Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

Should Early Aortic Valve Replacement Be Indicated in Asymptomatic Severe Aortic Stenosis?

A Meta-Analysis of Randomized Clinical Trials. The management of aortic stenosis in asymptomatic patients remains a matter of...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Predilatation in Self-Expanding Valves

TAVI has become the treatment of choice in specific scenarios. However, predilatation (PRD) remains a matter of...
Dr. Carlos Fava -
Learn More
Mitral valve

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...
Dr. Carlos Fava -
Learn More
Structural Heart Disease

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...
Dr. Omar Tupayachi -
Learn More
Pharmacology

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

TRIPLACE Registry: Conduction Disorders Following Transcatheter Tricuspid Valve Replacement

Tricuspid regurgitation (TR) has become increasingly common and has been associated to hospitalization for cardiac failure and...
Dr. Carlos Fava -
Learn More
Structural heart disease

Conduction Disorders in TAVR: Is Colchicine Useful?

TAVR has shown significant benefit and is increasingly used in severe aortic stenosis, especially in lower risk...
Dr. Carlos Fava -
Learn More
Structural heart disease

Post TAVR Conduction Disturbances: Same Day Permanent Pacemaker Implantation

TAVR has consolidated as standard of care for aortic stenosis. In recent years, high volume centers have...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy